References
- Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 2013; 5:171ra17; PMID:23390247; https://doi.org/10.1126/scitranslmed.3004828
- Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez L, Aisner J, et al. First-in-Human Clinical Trial of Oral ONC201 in patients with refractory solid tumors. Clin Cancer Res 2017; PMID:28331050; https://doi.org/10.1158/1078-0432.CCR-16-2658
- Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget 2017; PMID:28562358; https://doi.org/10.18632/oncotarget.17837
- Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 2016; 7:74380-92; PMID:27602582; https://doi.org/10.18632/oncotarget.11814
- Jacob NT, Lockner JW, Kravchenko VV, Janda KD. Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL. Angew Chem Int Ed Engl. 2014; 53:6628-31; PMID:24838721; https://doi.org/10.1002/anie.201402133
- Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, et al. Preclinical evaluation of the imipridone family, analogues of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle 2017; PMID:28489985; https://doi.org/10.1080/15384101.2017.1325046
- Dolma S, Selvadurai HJ, Lan X, Lee L, Kushida M, Voisin V, Whetstone H, So M, Aviv T, Park N, et al. Inhibition of Dopamine receptor D4 impedes autophagic flux, proliferation, and survival of Glioblastoma stem cells. Cancer Cell 2016; 29:859-73; PMID:27300435; https://doi.org/10.1016/j.ccell.2016.05.002